title: A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.
abstract: Myelofibrosis (MF) is a hematologic neoplasm arising as a primary disease or secondary to other myeloproliferative neoplasms (MPNs). Both primary and secondary MF are uniquely associated with progressive bone marrow fibrosis, displacing normal hematopoietic cells from the marrow space and disrupting normal production of mature blood cells. Activation of the JAK2 signaling pathway in hematopoietic stem cells commonly causes MF, and ruxolitinib, a drug targeting this pathway, is the treatment of choice for many patients. However, current measures of disease status in MF do not necessarily predict response to treatment with ruxolitinib or other drugs in MF. Bone marrow biopsies are invasive and prone to sampling error, while measurements of spleen volume only indirectly reflect bone marrow status. Toward the goal of developing an imaging biomarker for treatment response in MF, we present preliminary results from a prospective clinical study evaluating parametric response mapping (PRM) of quantitative Dixon MRI bone marrow fat fraction maps in four MF patients treated with ruxolitinib. PRM allows for the voxel-wise identification of significant change in quantitative imaging readouts over time, in this case the bone marrow fat content. We identified heterogeneous response patterns of bone marrow fat among patients and within different bone marrow sites in the same patient. We also observed discordance between changes in bone marrow fat fraction and reductions in spleen volume, the standard imaging metric for treatment efficacy. This study provides initial support for PRM analysis of quantitative MRI of bone marrow fat to monitor response to therapy in MF, setting the stage for larger studies to further develop and validate this method as a complementary imaging biomarker for this disease.
authors.affiliation: Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Gary D
authors.initials: GD
authors.lastname: Luker
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Huong Marie
authors.initials: HM
authors.lastname: Nguyen
authors.affiliation: Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Hoff
authors.affiliation: Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Galbán
authors.affiliation: Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA.
authors.forename: Diego
authors.initials: D
authors.lastname: Hernando
authors.affiliation: Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Chenevert
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Moshe
authors.initials: M
authors.lastname: Talpaz
authors.affiliation: Center for Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, MI, USA; Department of Biological Chemistry, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Ross
keywords: Magnetic resonance imaging; bone marrow; myelofibrosis; ruxolitinib